- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04208100
Pilot Evaluation of the Lutronic PicoPlus System for the Treatment of Benign Pigmented Lesions of the Hands
Study Overview
Detailed Description
Subjects will be enrolled to ensure a minimum number of subjects by skin type participate in the study as follows: FST I-II, at least 5 subjects; FST III, at least 10 subjects; FST IV, at least 5 subjects. Additionally, up to 20 training subjects will be enrolled that will be excluded from efficacy analysis, but will be included in safety analysis.
Standardized baseline and follow-up images will be taken using the sites' preferred camera system. No pre-treatment medication prior to study treatment.
Phase I: Study subjects will receive up to three treatments with the PicoPlus with the 595nm on one hand and the 660nm on the other hand. Subjects will receive the same wavelength for all treatments on each specific hand; treatments will alternate by subjects between the left side getting treated with the 595nm and the right side getting treated with the 660nm depending on enrollment. Treatments will be 30+7 days apart up to three treatments until desired clearance has been achieved.
Phase II: Up to 2 balancing treatments may be done if needed based on the investigator's discretion to achieve equal clearance on each hand utilizing the wavelength of the investigator's choice. Phase II will not be considered for efficacy endpoints.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Billerica, Massachusetts, United States, 01821
- William LoVerme, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, age 18 years and older.
- Subject in good health.
- Fitzpatrick Skin Type I to IV.
- Presence of benign pigmented lesions on hands.
- Understands and accepts the obligation not to undergo any other procedures in the treatment area.
- Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.
Subjects of childbearing potential must have a negative urine pregnancy test result and must not be lactating at the Screening Visit and be willing and able to use an acceptable method of birth control (e.g. barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will not be considered of childbearing potential if one of the following conditions is documented on the medical history:
- Postmenopausal for at least 12 months prior to study;
- Without a uterus and/or both ovaries; or
- Bilateral tubal ligation at least six months prior to study enrollment.
- Absence of physical or psychological conditions unacceptable to the investigator.
- Willingness and ability to provide written informed consent and HIPAA authorization prior to performance of any study-related procedure.
Exclusion Criteria:
- Healing disorders such as those caused by diabetes mellitus, connective tissue disease, radiation therapy, or chemotherapy.
- Subjects with a history of photosensitivity or diseases which may be stimulated by light at the wavelengths used, such as history of systemic Lupus Erythematosus, Pophyia, and Epilepsy.
- History of chronic drug or alcohol abuse.
- Inability to understand the protocol or to give informed consent.
- Subjects with a history of skin cancer or current condition of any other type of cancer or pre-malignant moles.
- Subjects who are pregnant, nursing, or anticipate a pregnancy during the length of the trial.
- History of keloid formation.
- Subjects with tattoos on the backs of the hands in the treatment area.
- History of surgical or cosmetic treatments in exposure area within the past six months.
- History of tanning or use of self-tanners in the past 4 weeks.
History of treatments that may irritate the skin in the treatment area such as depilatories, harsh chemicals, etc.) in the past 2 weeks.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pigmentary Clearance
Time Frame: 30 days
|
Percentage of pigmentary clearance by each wavelength in standard photographs from the 30-day visit post the last treatment in Phase I of the study using a score of 0-4, representing poor 0-24%, fair 25-49%, good 50-74%, excellent 75-95%, and complete 95%+ improvement was given at the day 30 follow-up visit post the last treatment as determined by three blinded physician evaluators comparing the baseline vs 30-day follow-up visit photographs.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinician Global Aesthetic Scale
Time Frame: 30 days
|
The Principal Investigator, sub-investigator or qualified clinician delegated by the principal investigator, will complete a Clinician Global Aesthetic Improvement Scale assessing overall aesthetic improvement by wavelength at the 30-day visit following the last treatment visit for Phase I of the study.
Scale ranging 1-Very Much Improved and 5-Worse.
|
30 days
|
Subject Global Aesthetic Scale
Time Frame: 30 days
|
2. The subject will complete a SGAIS assessing overall aesthetic improvement by wavelength at the 30-day visit following the last treatment visit for Phase I of the study.
Scale Ranging 1-Very Much Improved and 5-Worse.
|
30 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Satisfaction Questionnaire
Time Frame: 30 days
|
The subject will complete a Patient Satisfaction Questionnaire by wavelength at the 30-day visit following the last treatment visit for Phase I of the study.
There are 4 questions.
|
30 days
|
Pain Scale
Time Frame: 30 days
|
During all study treatments, the subject's pain levels will be monitored using a validated Numeric Rating Scale ranging from 0-10.
The maximum and average pain score will be recorded by wavelength.
|
30 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- L18007
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Benign Pigmented Lesions
-
Cynosure, Inc.CompletedBenign Pigmented Lesions | Wrinkle | Benign Vascular LesionsUnited States
-
LUTRONIC CorporationCompleted
-
Mahidol UniversityUnknownBenign Pigmented LesionsThailand
-
Syneron MedicalUnknownBenign Pigmented LesionsUnited States
-
Cynosure, Inc.CompletedAcne Scars | Wrinkle | Tattoo Removal | Benign Epidermal Pigmented Lesions | Benign Dermal Pigmented LesionsUnited States
-
Taipei Veterans General Hospital, TaiwanApollo Medical Optics, LtdTerminatedBenign Pigmented LesionsTaiwan
-
Candela CorporationCompletedBenign Pigmented Lesions | Facial WrinklesUnited States
-
Cynosure, Inc.CompletedBenign Pigmented and Vascular Lesions and ScarsUnited States
-
Syneron MedicalCompletedBenign Pigmented LesionsUnited States, China
-
Candela CorporationActive, not recruitingWrinkle | Pigmented LesionsUnited States
Clinical Trials on PicoPlus
-
LUTRONIC CorporationTerminatedMelasma | Tattoo; Pigmentation | Benign Pigmented LesionUnited States
-
LUTRONIC CorporationUnknown